1
|
Marsili F, Travaglini M, Stinco G, Manzoni R, Tiberio R, Prignano F, Mazzotta A, Cannavò SP, Cuccia A, Germino M, Bongiorno MR, Persechino S, Florio T, Pettinato M, Tabanelli M, Sarkar R, Aloisi E, Bartezaghi M, Orsenigo R. Effectiveness of cyclosporine A in patients with moderate to severe plaque psoriasis in a real-life clinical setting in Italy: the TRANSITION study. J DERMATOL TREAT 2020; 33:401-407. [PMID: 32349568 DOI: 10.1080/09546634.2020.1757017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Background: Cyclosporine A (CsA) is one of the systemic therapeutic options for moderate-to-severe psoriasis, based on its efficacy and rapidity of action. The current study investigated the response to CsA in patients with moderate-to-severe plaque psoriasis.Materials and Methods: TRANSITION was an observational, cross-sectional, multicentre study which evaluated the proportion of partial- and suboptimal-responders among patients with moderate-to-severe plaque psoriasis treated with continuous CsA for ≥12 weeks. Patients demonstrating a Psoriasis Area and Severity Index (PASI) response of ≥90, ≥75 and <90, ≥50 and <75 and <50 were defined as responders, suboptimal-responders, partial-responders, and non-responders, respectively.Results: A total of 196 patients (mean age, 46.6 years; 62.8% males) from 14 sites in Italy were evaluated. At the study visit, the mean (SD) PASI score was 4.2(5.5) compared with 15.3(7.1) prior to the last CsA cycle. For response categories, 39.8%, 22.4%, 16.8%, and 20.9% of patients were responders, suboptimal-responders, partial-responders, and non-responders to CsA treatment. Overall, 28.6% of patients permanently discontinued treatment with CsA (lack of efficacy [10.2%], poor tolerability and voluntary discontinuation [3.6% each], and other [11.7%]).Conclusion: Patients were only partially satisfied with CsA treatment, reporting measurable impact on quality of life. Only 40% patients showed a satisfactory response to CsA.
Collapse
Affiliation(s)
- F Marsili
- Unit of Dermatology, Versilia Hospital, Lido di Camaiore, Lucca, Italy
| | - M Travaglini
- Centro per la cura della Psoriasi, Hospital "Di Summa-Perrino", Brindisi, Italy
| | - G Stinco
- Institute of Dermatology, Department of Medicine, University Hospital, Udine, Italy
| | - R Manzoni
- Division of Dermatology, Azienda Sanitaria Locale of Biella, Ponderano, Italy
| | - R Tiberio
- SCDU Dermatology, AOU Maggiore della Carità, Novara, Italy
| | - F Prignano
- Department of Health Science Dermatology Unit, University of Florence, Firenze, Italy
| | - A Mazzotta
- Dermatology Unit, San Camillo-Forlanini Hospital, Rome, Italy
| | - S P Cannavò
- Dermatology Unit, University Hospital Policlinico "G. Martino", Messina, Italy
| | - A Cuccia
- Unit of Dermatology, San Donato Hospital, Arezzo, Italy
| | - M Germino
- Department of Dermatology, Hospital Policlinico Città di Udine, Udine, Italy
| | - M R Bongiorno
- Dermatology Unit, University Hospital Policlinico "P. Giaccone", Palermo, Italy
| | - S Persechino
- Dermatology Unit, NESMOS Department, S. Andrea Hospital, University of Rome "Sapienza", Rome, Italy
| | - T Florio
- Dermatology Unit, Hospital Di Venere-Carbonara di Bari, Bari, Italy
| | - M Pettinato
- Dermatology Unit, University Hospital "Policlinico-Vittorio Emanuele", Catania, Italy
| | - M Tabanelli
- U.O.C. Dermatologia Ravenna AUSL Romagna, Ospedale Santa Maria delle Croci, Ravenna, Italy
| | - R Sarkar
- Novartis Pharma AG, Basel, Switzerland
| | - E Aloisi
- Novartis Farma SpA, Origgio, Italy
| | | | | |
Collapse
|
2
|
Papini M, Cusano F, Romanelli M, Burlando M, Stinco G, Girolomoni G, Peris K, Potenza C, Offidani A, Bartezaghi M, Aloisi E, Costanzo A, Bianchi L, Bottoni U, Buligan C, Brazzelli V, Campanati A, Cantoresi F, Capo A, Cattaneo A, Dapavo P, Giglio M, Lernia V, Nuzzo S, Simone C, Dusi D, Fargnoli C, Flori L, Franchi C, Galluzzo M, Ghilardi A, Hansel K, Loconsole F, Lora V, Malagoli P, Malara G, Mastrandrea V, Megna M, Mercuri R, Musumeci L, Naldi L, Narcisi A, Orsini D, Pagnanelli G, Patrizi A, Pau M, Pellacani G, Persechino S, Piaserico S, Pietroleonardo L, Prignano F, Reseghetti A, Russo F, Sirna R, Skroza N, Stingeni L, Trevisini S, Zane C, Zichichi L, Zini A. Secukinumab shows high efficacy irrespective of
HLA‐Cw6
status in patients with moderate‐to‐severe plaque‐type psoriasis: results from extension phase of the SUPREME study. Br J Dermatol 2019; 181:413-414. [DOI: 10.1111/bjd.18013] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
3
|
Costanzo A, Bianchi L, Flori M, Malara G, Stingeni L, Bartezaghi M, Carraro L, Castellino G. HLA-Cw6 allele and efficacy of secukinumab. Br J Dermatol 2018. [DOI: 10.1111/bjd.17218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
4
|
Costanzo A, Bianchi L, Flori M, Malara G, Stingeni L, Bartezaghi M, Carraro L, Castellino G. HLA-Cw6 等位基因和苏金单抗的疗效. Br J Dermatol 2018. [DOI: 10.1111/bjd.17232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
5
|
Costanzo A, Bianchi L, Flori M, Malara G, Stingeni L, Bartezaghi M, Carraro L, Castellino G. Secukinumab shows high efficacy irrespective of HLA-Cw6
status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. Br J Dermatol 2018; 179:1072-1080. [DOI: 10.1111/bjd.16705] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/06/2018] [Indexed: 12/16/2022]
Affiliation(s)
- A. Costanzo
- Dermatology Unit; Department of Biomedical Sciences; Humanitas University; Via Alessandro Manzoni 113 Rozzano-Milan 20089 Italy
- Skin Pathology Laboratory; IRCCS Istituto Clinico Humanitas; Via Alessandro Manzoni 113 Rozzano-Milan 20089 Italy
| | - L. Bianchi
- Dermatology; Department of Systems Medicine; Policlinico di Tor Vergata; University of Rome Tor Vergata; Viale Oxford 81 Rome 00133 Italy
| | - M.L. Flori
- Dermatology Section; Department of Clinical Medicine and Immunological Science; University of Siena; Hospital S. Maria alle Scotte; viale Bracci Siena Italy
| | - G. Malara
- Dermatology Department; Grande Ospedale Metrapolitano; Bianchi Melacrino Morelli; 89124 Reggio Calabria Italy
| | - L. Stingeni
- Section of Clinical, Allergological and Venereological Dermatology; Department of Medicine; University of Perugia; Piazza Menghini 1 Perugia 06129 Italy
| | - M. Bartezaghi
- Novartis Farma S.p.A.; Via Saronnino Origgio VA 21042 Italy
| | - L. Carraro
- Novartis Farma S.p.A.; Via Saronnino Origgio VA 21042 Italy
| | - G. Castellino
- Novartis Farma S.p.A.; Via Saronnino Origgio VA 21042 Italy
| | | |
Collapse
|